Published in Heart Fail Rev on January 01, 2005
Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol (2009) 1.05
PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. Am J Physiol Heart Circ Physiol (2011) 1.03
Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action. Steroids (2010) 0.92
Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens (2011) 0.89
Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. Am J Physiol Regul Integr Comp Physiol (2007) 0.87
Is the mineralocorticoid receptor a potential target for stroke prevention? Clin Sci (Lond) (2008) 0.85
The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens (2016) 0.77
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Malignant Hypertension Produced by Treatment with Desoxycorticosterone Acetate and Sodium Chloride. Can Med Assoc J (1943) 9.50
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med (2001) 2.48
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int (2003) 2.13
CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES. Am J Surg (1964) 2.06
Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation (2000) 1.87
Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension (2003) 1.86
Role of aldosterone in the remnant kidney model in the rat. J Clin Invest (1996) 1.65
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 1.50
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension (1998) 1.46
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int (2000) 1.44
Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol (2001) 1.36
Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension (1999) 1.34
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis (1999) 1.24
Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant (1995) 1.15
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation (2003) 1.12
Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol (2001) 1.11
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol (1995) 1.10
Aldosterone in the development and progression of renal injury. Kidney Int (2004) 1.10
Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int (2000) 1.10
Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab (2001) 1.09
Aldosterone as a mediator in cardiovascular injury. Cardiol Rev (2002) 1.03
Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol (2004) 1.02
Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens (2004) 1.00
Potassium's cardiovascular protective mechanisms. Am J Physiol (1995) 0.98
Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res (2003) 0.98
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol (2004) 0.94
Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol (1993) 0.92
Increased superoxide anion generation and altered vasoreactivity in rabbits on low-potassium diet. Am J Physiol (1998) 0.89
Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension (1998) 0.89
The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke (1997) 0.88
Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int (1992) 0.87
Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol (1999) 0.87
Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol (2004) 0.87
Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens (1991) 0.86
Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med (1976) 0.85
Amiloride reduces stroke and renalinjury in stroke-prone hypertensive rats. Am J Hypertens (2003) 0.83
Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl (1993) 0.83
Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens (1995) 0.81
Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol (2003) 0.81
Renal pathology in patients with primary hyperaldosteronism secondary to an adrenal cortical adenoma. Urology (1996) 0.80
Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension. Hypertension (2000) 0.77
Complete prevention of cerebral accidents in malignant hypertension. Circ Res (1956) 0.77
Influence of adrenalectomy and steroid replacement on heart citrate synthase levels. Am J Physiol (1984) 0.76
Potential importance of glomerular citrate synthase activity in remnant nephropathy. Kidney Int (2003) 0.75
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int (2003) 2.13
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
The diversity present in 5140 human mitochondrial genomes. Am J Hum Genet (2009) 1.90
Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol (2012) 1.89
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich) (2007) 1.63
Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. Am J Physiol Heart Circ Physiol (2008) 1.52
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest (2003) 1.52
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res (2003) 1.22
Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation (2003) 1.16
Heme oxygenase-2 deficiency contributes to diabetes-mediated increase in superoxide anion and renal dysfunction. J Am Soc Nephrol (2006) 1.13
Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension (2002) 1.10
Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol (2002) 1.03
Aldosterone as a mediator in cardiovascular injury. Cardiol Rev (2002) 1.03
Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci (2008) 1.03
HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation. Am J Physiol Renal Physiol (2009) 1.01
Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. Am J Physiol Renal Physiol (2007) 1.01
Adoptive transfer of syngeneic bone marrow-derived cells in mice with obesity-induced diabetes: selenoorganic antioxidant ebselen restores stem cell competence. Am J Pathol (2009) 1.00
Idiopathic nodular glomerulosclerosis in a non-diabetic hypertensive smoker--case report and review of literature. Nephrol Dial Transplant (2006) 0.99
Adverse host factors exacerbate occult HIV-associated nephropathy. Am J Pathol (2011) 0.94
Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens (2007) 0.93
Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. Kidney Int (2004) 0.90
Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol (2008) 0.89
Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab (2003) 0.89
HIV-associated nephropathy: role of mammalian target of rapamycin pathway. Am J Pathol (2010) 0.89
Human immunodeficiency virus downregulates podocyte apoE expression. Am J Physiol Renal Physiol (2009) 0.88
Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl (2008) 0.86
Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab (2008) 0.85
Male gender and not the severity of hypertension is associated with end-organ damage in aged stroke-prone spontaneously hypertensive rats. Am J Hypertens (2005) 0.84
Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol (2004) 0.83
Amiloride reduces stroke and renalinjury in stroke-prone hypertensive rats. Am J Hypertens (2003) 0.83
HIV-associated nephropathy: role of AT2R. Cell Signal (2011) 0.83
RepeatAround: a software tool for finding and visualizing repeats in circular genomes and its application to a human mtDNA database. Mitochondrion (2006) 0.81
Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol (2003) 0.81
Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich) (2007) 0.80
Colorectal surgical mortality and morbidity in elderly patients: comparison of POSSUM, P-POSSUM, CR-POSSUM, and CR-BHOM. Int J Colorectal Dis (2014) 0.79
mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN. Am J Physiol Renal Physiol (2013) 0.78
Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J Clin Hypertens (Greenwich) (2008) 0.78
MtDNA GeneExtractor: a computer tool for mtDNA gene/region information extraction. Mitochondrion (2008) 0.76
Sodium transport antagonism reduces thrombotic microangiopathy in stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol (2004) 0.76
Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens (2008) 0.75
Is enough being done to control hypertension? An evaluation of blood pressure control patterns in a community-based setting. J Clin Hypertens (Greenwich) (2009) 0.75
Diffuse infiltrative lymphocytosis syndrome presenting as reversible acute kidney injury associated with Gram-negative bacterial infection in patients with newly diagnosed HIV infection. Am J Kidney Dis (2011) 0.75
Management of brain-dead donors outside the intensive care unit: a necessary recourse. Eur J Emerg Med (2015) 0.75